Impacts of COVID-19 and elective surgery cancellations on platelet supply and utilization in the Canadian Province of British Columbia.


Journal

Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606

Informations de publication

Date de publication:
Feb 2022
Historique:
revised: 25 06 2021
received: 14 04 2021
accepted: 26 06 2021
pubmed: 27 7 2021
medline: 12 2 2022
entrez: 26 7 2021
Statut: ppublish

Résumé

The coronavirus disease 2019 (COVID-19) pandemic raised concerns about the vulnerability of platelet supply and the uncertain impact of the resumption of elective surgery on utilization. We report the impact of COVID-19 on platelet supply and utilization across a large, integrated healthcare system in the Canadian province of British Columbia (BC). Historical platelet use in BC by indication was compiled for fiscal year 2010/2011-2019/2020. Platelet collections, initial daily inventory and disposition data were assessed pre-COVID-19 (1 April 2018-15 March 2020) and for two COVID-19 time periods in BC: a shutdown phase with elective surgeries halted (16 March-17 May, 2020) and a renewal phase when elective surgeries resumed (18 May-27 September 2020); comparisons were made provincially and for individual health authorities. Historically, elective surgeries accounted for 10% of platelets transfused in BC. Initial daily supplier inventory increased from baseline during both COVID-19 periods (93/90 units vs. 75 units pre-COVID-19). During the shutdown phase, platelet utilization decreased 10.4% (41 units/week; p < 0.0001), and remained significantly decreased during the ensuing renewal period. Decreased platelet utilization was attributed to fewer transfusions during the shutdown phase followed by a decreased discard/expiry rate during the renewal phase compared to pre-COVID-19 (15.2% vs. 18.9% pre-COVID-19; p < 0.0001). Differences in COVID-19 platelet utilization patterns were noted between health authorities. Decreased platelet utilization was observed in BC compared to pre-COVID-19, likely due to a transient reduction in elective surgery as well as practice and policy changes triggered by pandemic concerns.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
The coronavirus disease 2019 (COVID-19) pandemic raised concerns about the vulnerability of platelet supply and the uncertain impact of the resumption of elective surgery on utilization. We report the impact of COVID-19 on platelet supply and utilization across a large, integrated healthcare system in the Canadian province of British Columbia (BC).
MATERIALS AND METHODS METHODS
Historical platelet use in BC by indication was compiled for fiscal year 2010/2011-2019/2020. Platelet collections, initial daily inventory and disposition data were assessed pre-COVID-19 (1 April 2018-15 March 2020) and for two COVID-19 time periods in BC: a shutdown phase with elective surgeries halted (16 March-17 May, 2020) and a renewal phase when elective surgeries resumed (18 May-27 September 2020); comparisons were made provincially and for individual health authorities.
RESULTS RESULTS
Historically, elective surgeries accounted for 10% of platelets transfused in BC. Initial daily supplier inventory increased from baseline during both COVID-19 periods (93/90 units vs. 75 units pre-COVID-19). During the shutdown phase, platelet utilization decreased 10.4% (41 units/week; p < 0.0001), and remained significantly decreased during the ensuing renewal period. Decreased platelet utilization was attributed to fewer transfusions during the shutdown phase followed by a decreased discard/expiry rate during the renewal phase compared to pre-COVID-19 (15.2% vs. 18.9% pre-COVID-19; p < 0.0001). Differences in COVID-19 platelet utilization patterns were noted between health authorities.
CONCLUSION CONCLUSIONS
Decreased platelet utilization was observed in BC compared to pre-COVID-19, likely due to a transient reduction in elective surgery as well as practice and policy changes triggered by pandemic concerns.

Identifiants

pubmed: 34309031
doi: 10.1111/vox.13180
pmc: PMC8447158
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

251-258

Subventions

Organisme : None

Informations de copyright

© 2021 International Society of Blood Transfusion.

Références

Transfusion. 2021 Jan;61(1):303-312
pubmed: 33098328
Transfusion. 2020 Jul;60(7):1470-1475
pubmed: 32445417
Vox Sang. 2021 May;116(5):574-580
pubmed: 33135226
Transfusion. 2020 Dec;60(12):2859-2866
pubmed: 32856307
Vox Sang. 2022 Feb;117(2):251-258
pubmed: 34309031
Transfus Apher Sci. 2020 Oct;59(5):102868
pubmed: 32646793
Transfusion. 2021 Jan;61(1):72-77
pubmed: 33029791
Transfusion. 2021 Mar;61(3):692-698
pubmed: 33215718
Br J Haematol. 2020 Nov;191(3):382-385
pubmed: 32640484
Transfusion. 2021 Apr;61(4):1102-1111
pubmed: 33452826
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Lab Med. 2021 Jan 4;52(1):10-15
pubmed: 32929506
Vox Sang. 2021 May;116(5):497-503
pubmed: 33103772

Auteurs

Kevin E Shopsowitz (KE)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Christina Lim (C)

BC Provincial Blood Coordinating Office, Vancouver, British Columbia, Canada.

Andrew W Shih (AW)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Pathology and Laboratory Medicine, Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada.
Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.

Nick Fishbane (N)

BC Provincial Blood Coordinating Office, Vancouver, British Columbia, Canada.

Brian R Berry (BR)

Department of Pathology, Vancouver Island Health Authority, Victoria, British Columbia, Canada.

Mark Bigham (M)

Canadian Blood Services, Vancouver, British Columbia, Canada.

Tanya Petraszko (T)

Canadian Blood Services, Vancouver, British Columbia, Canada.
Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Jacqueline Trudeau (J)

Department of Anesthesia, Pharmacology, and Therapeutics, University of British Columbia, Vancouver, British Columbia, Canada.

Maureen Wyatt (M)

Department of Pathology and Laboratory Medicine, Interior Health Authority, Kelowna, British Columbia, Canada.

Matthew T S Yan (MTS)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Canadian Blood Services, Vancouver, British Columbia, Canada.
Department of Pathology and Laboratory Medicine, Fraser Health Authority, New Westminster, British Columbia, Canada.

Douglas Morrison (D)

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
BC Provincial Blood Coordinating Office, Vancouver, British Columbia, Canada.
Department of Pathology and Laboratory Medicine, Children's and Women's Health Centre of BC, Vancouver, British Columbia, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH